14 Mar 2014

BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 in Immunotherapy

a-
A+
Customize font size:
Share:
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that an Issue of Notification has been received from the United States Patent and Trademark Office (USPTO) for U.S. Patent  No. 8,663,651, which includes claims to protect the use of BL-8040’s composition for enhancing immune responses to an antigen, such as a tumor-associated antigen. The issued patent has a term extending to October 2029. This patent is part of BL-8040’s expanding patent portfolio, which includes 13 issued patents and 25 patent applications pending worldwide, providing a strong intellectual property estate around BL-8040.
 
"We are very pleased with this newly issued patent for BL-8040, which further strengthens the patent position we have for our leading oncology program. We view BL-8040 as a platform for multiple oncological and hematological indications, and robust patent protection provides us with the foundation to pursue these multiple indications for the BL-8040 platform,” stated Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx. "BL-8040 is currently undergoing a Phase 2 trial for the treatment of acute myeloid leukemia and is expected to enter a Phase 1 trial for stem cell mobilization in the 2nd quarter of 2014. We expect top-line results for both of these clinical studies towards the end of the year or early next year,” concluded Dr. Savitsky.